Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS): 2 pipeline candidates · 2 upcoming catalysts · ~21 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
20.9 months
0% dilution
Lead: Phase 2
2 candidates
2 upcoming, next in ~166d
2 buys · 37 sells (180d)
A transparent, data-derived signal for Mineralys Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.1B
Cash
$112.8M
Quarterly Burn
$39.5M
Runway
20.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| lorundrostat | Phase 2 |
| lorundrostat 25mg+sglt2i qd | Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Binary FDA approval decision — outcome can sharply revalue the stock.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
215
Total value held
$2.46B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 7,692,750 | $208.4M |
| samsara biocapital, llc | 5,871,018 | $159.0M |
| vanguard capital management llc | 4,908,726 | $133.0M |
| fmr llc | 4,861,104 | $131.7M |
| blackrock, inc. | 4,481,582 | $121.4M |
| wellington management group llp | 3,359,068 | $91.0M |
| caption management, llc | 3,273,400 | $88.7M |
| state street corp | 2,935,940 | $79.5M |
| caligan partners lp | 2,772,654 | $75.1M |
| laurion capital management lp | 2,232,040 | $60.5M |
Showing top 10 of 215 institutional holders of Mineralys Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Mineralys Therapeutics, Inc.'s pipeline?
Mineralys Therapeutics, Inc. (MLYS) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Mineralys Therapeutics, Inc.'s lead drug candidate?
Mineralys Therapeutics, Inc.'s most advanced tracked candidate is lorundrostat (Phase 2) for Obstructive Sleep Apnea; Hypertension.
What is Mineralys Therapeutics, Inc.'s next catalyst?
Mineralys Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundro" — expected December 1, 2026.
What is Mineralys Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Mineralys Therapeutics, Inc. has approximately 20.9 months of cash runway.
What is Mineralys Therapeutics, Inc.'s market capitalization?
Mineralys Therapeutics, Inc.'s market capitalization is approximately $2.1B.
Get the full picture on Mineralys Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.